Anemia News Archive
Researchers find no significant difference in the median erythropoietin resistance index between patients with versus without residual renal function.
To shed light on the often-challenging management of this common condition, a case of a hypothetical patient was presented to a doctor who specializes in advanced heart failure and transplant cardiology.
High doses of iron are associated with a significantly higher risk of cardiovascular disease, regardless of the dose of erythropoiesis-stimulating agent.
Study results show that the phosphate binder was superior to placebo in raising hemoglobin levels in non-dialysis-dependent CKD patients with iron-deficiency anemia.
Intravenous iron and erythropoietin produced a similar hemoglobin response among hemodialysis patients with moderate anemia.
The group targeting higher hemoglobin values experienced less decline in graft function.
HD patients with untreated or ineffectively treated anemia prior to dialysis initiation were more likely to die than those who had consistently well-treated anemia.
In a study, end-stage renal disease was 31% more likely to develop in CKD patients with versus without anemia.
CKD patients in the 3rd and 4th quartiles of c-terminal serum fibroblast growth factor 23 had a 74% and 73% higher risk for anemia compared with those in the 1st quartile.
Proteinuria and renin-angiotensin-aldosterone system inhibitors are independently associated with a significant 6-fold increased odds for anemia in patients with diabetic nephropathy.
No data to suggest that nonvoluntary nature of donations compromises safety of blood products.
Findings based upon time costs of preparation and administration per patient.
In a randomized study of patients with heart failure, including some with concurrent chronic kidney disease, patients who received vitamin D supplements or placebo had similar changes in hemoglobin levels over 36 months.
Anemia much more common among patients who did not have close follow-up with weight-loss surgeon
In a survey, hemodialysis patients were willing to accept medication risks to avoid red blood cell transfusion.
Study of Japanese individuals showed that anemia increased mortality risk even in the absence of chronic kidney disease.
The proportion of patients with serum phosphorus levels within target range rose from 22% to 65% within 6 months of starting ferric citrate treatment.
Up to a 49% higher risk of death observed in patients who had a 400 ng/mL increase in serum ferritin from baseline values compared with patients who had relatively stable ferritin levels.
Japanese researchers conclude that a serum ferritin level below 90 ng/mL and TSAT of 20% or higher was optimal for achieving a hemoglobin level of 10 g/dL or higher.
Researchers used pulse wave analysis to measure subendocardial viability ratio, a measure of myocardial perfusion, and its association with hemoglobin.
As red blood cell distribution width increases, so does the risk of death from any cause.
Anemic patients were 41% and 80% more likely to have coronary artery disease and peripheral artery disease than non-anemic patients.
Intravenous iron should be strongly considered for patients treated with ESAs or hemodialysis, according to reviewers.
In type 2 diabetic male patients, a low testosterone level was found to be associated with anemia. These findings are consistent with previous reports.
Significantly more patients treated with ferric citrate increased their hemoglobin levels by 1 g/dL or more over 8 weeks.
The prevalence of low hemoglobin levels increases with declining renal function.
Ferric pyrophosphate citrate delivered via dialysate or intravenously rapidly donates iron to transferrin and is rapidly cleared from the circulation.
Company asks FDA to approve ferric citrate for iron deficiency anemia in patients with non-dialysis dependent chronic kidney disease.
Older men on TRT versus placebo for 1 year had improved hemoglobin levels and volumetric bone mineral density and estimated bone strength.
CKD patients with larger erythrocyte volumes had more than triple the risk of dying from cardiovascular causes, researchers reported.
Investigators observed no difference in hemoglobin level between transplant recipients and non-transplant CKD patients starting hemodialysis.
New and established peritoneal dialysis patients both showed this trend.
In a study 52.1% of patients receiving ferric citrate attained a 1.0 g/dL or greater increase in hemoglobin compared with just 19.1% receiving placebo.
New study finds no difference in all-cause and cause-specific mortality between iron sucrose and sodium ferric gluconate complex.
Use of ESAs declined while use of blood transfusions increased between 2008 and 2012.
The surface chemistry of the polymer reacts to the pH level of blood as it travels through the body.
The condition is present in more than half of Medicare patients with stage 3-5 chronic kidney disease.
US patients receive higher intravenous iron and ESA doses during the first year of hemodialysis compared with those in Europe.
Low vitamin D status was associated with a 2-fold higher risk for anemia.
Results were homogeneous, with differences in absolute mortality consistently less than 1% among the most extreme exposure categories.
Pending future research, patients should avoid taking more than 120 mg per day.
SHPT patients who received 6 months of cinacalcet treatment had a 10% increase in the odds of reaching target hemoglobin levels.
Study finds no increased risk of major adverse cardiovascular events and death.
Factors including low preoperative mean arterial BP tied to increases in eGFR, kidney injury.
Management strategy also is associated with reduced mortality risk, but not achievement of hemoglobin targets.
End-stage renal disease is 32% more likely to develop in patients with C-reactive protein levels of 6.9 mg/L or higher vs 3.0 mg/L or lower.
Other risk factors include reduced muscle mass and lower levels of physical activity.
A recent study resulted in a new definition of less-than-optimal response to erythropoiesis-stimulating agents.
A hemoglobin level of 10.5 g/dL offers the optimal balance of cost and quality adjusted life years, researchers conclude.
The odds of developing anemia were 2-fold greater among patients with than without diabetes mellitus.
Anemia was associated with impaired activity levels at CKD stages 3, 4, and dialysis.
IV administration of vitamin B6 did not improve anemia or abnormal bone metabolism over 6 months.
Average weekly doses greater than 70 µg/week was associated with a 77% increased risk of cancer compared with no ESA exposure.
A high erythropoietin resistance index was associated with triple the risk for death from any cause.
Patients provided small doses of intravenous iron per treatment achieved higher hemoglobin levels than patients receiving weekly iron.
In a small study, 82% of patients had iron overload prior to hemodialysis initiation.
Less than half of anemic patients were prescribed ESAs or iron in the US and France, and a high percentage overall did not have iron indices measured.
Investigators find that the normalized mean ESA dose decreases as patients' elevation of residence increases.
Researchers confirmed higher dose conversion ratios in Taiwanese patients with stable hemoglobin.
New findings implicate transferrin saturation and nutritional status assessed by albumin.
After 54 weeks of treatment with testosterone undecanoate, anemia prevalence decreased from 29.6% to 10%.
Trend is independent of intravenous iron use and exposure to erythropoiesis-stimulating agents.
No new adverse events observed in patients with underlying cardiovascular risk factors who switched to continuous erythropoietin receptor activator.
Greater hyporesponsiveness to erythropoiesis-stimulating agents was associated with increased PLR ratios.
Observed rates of all-cause and cardiovascular mortality and myocardial infarction were consistent with expected rates, study shows.
Researchers observe significantly higher levels of albumin and hemoglobin and better calcium and phosphate metabolism.
Based on effect of erythropoietin-stimulating agents for higher hemoglobin targets.
In a phase 2 trial, roxadustat maintained hemoglobin levels over 19 weeks as well as epoetin alfa.
In a case-control study, the treatment did not adversely affect mortality or recovery from AKI.
Study shows benefit of initiating epoetin beta therapy at hemoglobin levels not less than 10 g/dL in non-dialysis CKD patients.
Treatment corrects anemia and improves quality of life, according to a systemic review.
Six-months of supplementation has no impact on epoetin utilization in HD patients with low 25(OH)D.
In a study, investigators observed that levels were higher in those with stage 3a than stage 3b chronic kidney disease.
The estimated potential staff time savings totaled 23 hours for an average facility with 70 patients, researchers found.
Rates of death and important non-fatal outcomes between ferumoxytol and iron sucrose or sodium ferric gluconate do not differ significantly.
For ICU patients, hemoglobin level thresholds vary with presence of comorbid heart disease.
Risk of anaphylaxis associated with IV iron highest for iron dextran, lowest for iron sucrose.
Having hemoglobin 9-11 g/dL prior to dialysis provided the best life expectancy.
It is unclear whether RDW is a risk factor for early death or a byproduct of biological and metabolic imbalances.
Patients prescribed the lipid-lowering agents were less likely to exhibit hyporesponsiveness to the medications.
Study finds no gender differences in parathyroid hormone, ferritin, Kt/V, or age.
In a study, the mean hemoglobin level increased significantly in hemodialysis patients with functional iron deficiency.
The association is independent of anemia, according to researchers.
Patients with vs. without protein-energy wasting syndrome had a significantly lower mean hemoglobin level.
Hepatitis C viral infection found to increase likelihood of requiring blood transfusions and hemoglobin levels dropping below 8.5 g/dL.
Iron deficiency may contribute to the relationship between proteinuria and excess FGF-23, researchers suggested.
The odds of major adverse cardiac events were 46% to 76% higher in anemic vs. non-anemic patients.
Unlike serum ferritin, transferrin saturation demonstrated an ability to predict the need for intravenous iron and ESA.
RED-HF study confirms the increased stroke risk observed in TREAT.
Successfully treating anemia in pre-dialysis CKD patients appears to prevent left ventricular remodeling.
Kidney disease patients with macroalbuminuria were 86% more likely to be anemic.
Trial stopped early due to a higher risk of serious cardiovascular events and infections with IV iron versus oral iron.
It was associated with a 15% reduced risk of early death among pre-dialysis, stage 5 chronic kidney patients treated with ESAs.
It reduces dose requirements and lowers the risk of death and hospitalization for cardiovascular complications compared with IV administration.
Researchers find link in the non-dialysis population.
Proteinuria, hyperphosphatemia, anemia linked more rapid annual decline in eGFR.
The Food and Drug Administration (FDA) has strengthened an existing warning regarding serious and potentially fatal allergic reactions that can occur with Feraheme (ferumoxytol; AMAG Pharmaceuticals).
The medication may represent a new treatment option for dialysis patients, researchers concluded.
Soluble ferric pyrophosphate is given to hemodialysis patients via dialysate.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)